US4022878A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compounds for producing specific antibodies
Assignee: Biological Developments Inc
•
Filing: 1974-11-29
•
Granted: 1977-05-10
•
Expires: 1994-11-29
Abstract
Abstract This invention relates to a novel method of producing purified antibodies which are truly specific for native homologous hapten or antigen by administering artificial antigens as described therein to an antibody producing host followed by isolation and purification.
Inventors
- 👤 Stanley J. Gross
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 17:41
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/94; G01N33/9406; G01N33/53; G01N33/531; Y; Y10; Y10S; Y10S436/00; Y10S436/804; Y10S436/815; Y10S436/816; Y10S436/817; Y10S436/823
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
138 words
In the method of assaying for the presence and quantity of a hapten or an antigen employing radiation-based immunoassaying, the improvement which comprises producing antibodies which are specific for native homologous hapten or antigen comprising (1) administering to an animal an antibody producing dose of an artificial antigen wherein an immunogenic carrier is bound to a hapten through a ring atom of the hapten by replacement of a biologically inactive substituent, where such substituent is not a determinant, in such manner as to leave the determinant functional groups of said hapten free, (2) obtaining a crude mixture containing antibodies from said animal, (3) isolating antibodies from said crude mixture, (4) and employing said antibodies in a radiation-based immunoassay together with a radiation label, whereby the amount of said antibodies reacting with the hapten or antigen can be measured.
Claim 2
Dependent Claim
138 words
In the method of assaying for the presence and quantity of a hapten or an antigen employing radiation-based immunoassaying, the improvement which comprises producing antibodies which are specific for native homologous hapten or antigen comprising (1) administering to an animal an antibody producing dose of an artificial antigen wherein an immunogenic carrier is bound to a hapten through a ring atom of the hapten by replacement of a biologically inactive substituent, where such substituent is not a determinant, in such manner as to leave the determinant functional groups of said hapten free, (2) obtaining a crude mixture containing antibodies from said animal, (3) isolating antibodies from said crude mixture, (4) and employing said antibodies in a radiation-based immunoassay together with a radiation label, whereby the amount of said antibodies reacting with the hapten or antigen can be measured.
Claim 3
Dependent Claim
66 words
The method of claim 1 wherein the bond between said ring atom and said immunogenic carrier is covalent, said bond being through a linking group derived from a linking agent containing one functional group capable of covalently bonding to said ring atom and another functional group capable of covalently bonding to said carrier, by coupling said functional groups to said ring atom and said immunogenic carrier.
Claim 4
Dependent Claim
33 words
The method of claim 2 wherein said hapten or antigen is selected from the group consisting of estradiol-17β, estrone, estriol, tetrahydrocannabinols, opium alkaloids, barbiturates, amphetamines, thyroxin, catechol amines, prostaglandines, vitamins, cocaine and pentazocine.
Claim 5
Dependent Claim
13 words
The method of claim 3 wherein said immunogenic carrier is an immunogenic protein.
Claim 6
Dependent Claim
17 words
The method of claim 4 wherein said protein is bovine serum albumin, keyhole limpet hemocyanin, or immunogammaglobulin.
Claim 7
Dependent Claim
82 words
The method of claim 1 wherein the hapten is selected from the group consisting of estradiol-17β, estrone, estriol, Δ-9-tetrahydrocannabinol, morphine, heroin, codeine, methadone, pentazocine, amphetamine, thyroxin, phenobarbital lysergic acid and cocaine, wherein the bond between said ring atom and said immunogenic carrier is a covalent bond via a --N=N-- linkage, said linkage being a portion of a moiety capable of sustaining a diazonium ion, said moiety further including a linkage selected from the group consisting of amide, sulfonamide ether, ester or disulfide.
Claim 8
Dependent Claim
16 words
The method of claim 6 wherein said linkage between said moiety and said carrier is --CONH--.
Claim 9
Dependent Claim
26 words
the method of claim 7 wherein said immunogenic carrier is selected from the group consisting of bovine serum albumin, keyhole limpet hemocyanin, and human gamma globulin.
References Cited (Backward Citations)
US3709868A
Cited
US3901654A
Cited
US3766162A
Cited
US3809782A
Cited
US3884898A
Cited
US3843696A
Cited
US3878187A
Cited
US3867366A
Cited
US3888866A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-05-09 | 1980-11-08 | 1981-05-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-05-09 | 1984-11-08 | 1985-05-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-05-09 | 1988-11-08 | 1989-05-10 | $7700.00 | Window Closed / Lapsed |